Azitra Faces NYSE American Noncompliance and Delisting Risk

Azitra Inc ( (AZTR) ) has provided an update.

Azitra Inc., a clinical-stage biopharmaceutical company specializing in precision dermatology, is developing live biotherapeutic products including ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor–associated rash, supported by an AI-driven microbial strain library. Its programs target rare and treatment-resistant dermatologic conditions, positioning the company in a niche segment of the dermatology market.

On March 13, 2026, Azitra disclosed it had received a notice from NYSE American that it is not in compliance with the exchange’s stockholders’ equity requirement under Section 1003(a)(iii), after reporting $3.8 million in equity as of December 31, 2025 and losses over the past five fiscal years. The exchange has given the company until April 1, 2027 to regain compliance under an existing plan or face potential delisting proceedings, a risk underscored by a going-concern warning in its latest audited financial statements, although trading of its shares and SEC reporting obligations continue unchanged.

During this plan period, Azitra will remain listed on NYSE American but will undergo quarterly monitoring to assess its progress in rebuilding equity and meeting continued listing standards. The company is exploring multiple funding options to shore up its financial position, a process that will be closely watched by investors given the combined pressures of ongoing losses, compliance deadlines and the possibility of delisting if its turnaround efforts fall short.

The most recent analyst rating on (AZTR) stock is a Hold with a $0.17 price target. To see the full list of analyst forecasts on Azitra Inc stock, see the AZTR Stock Forecast page.

Spark’s Take on AZTR Stock

According to Spark, TipRanks’ AI Analyst, AZTR is a Underperform.

The score is primarily constrained by weak financial performance—persistent losses, heavy cash burn, and the sharp 2025 deterioration—suggesting elevated funding risk. Technicals add pressure due to a downtrend and negative MACD. Valuation is hard to justify on earnings given the negative P/E, while the canceled stockholder meeting is an additional negative overhang.

To see Spark’s full report on AZTR stock, click here.

More about Azitra Inc

Azitra Inc. is a clinical-stage biopharmaceutical company focused on precision dermatology therapies. Its lead candidate, ATR-12, is an engineered S. epidermidis strain in a Phase 1b trial for Netherton syndrome, while ATR-04 targets EGFR inhibitor–associated rash and has U.S. FDA Fast Track designation, both developed from a proprietary AI-enhanced microbial platform.

Average Trading Volume: 1,421,802

Technical Sentiment Signal: Sell

Current Market Cap: $2.91M

For a thorough assessment of AZTR stock, go to TipRanks’ Stock Analysis page.